• +1-646-491-9876
    • +91-20-67278686

    Search

    Osteosarcoma-Pipeline Review H2 2017

    Osteosarcoma-Pipeline Review H2 2017

    • Report Code ID: RW00011022673
    • Category Life Sciences
    • No. of Pages 287
    • Publication Month Aug-17
    • Publisher Name Global Markets Direct
    Osteosarcoma-Pipeline Review, H2 2017

    Summary

    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma-Pipeline Review, H2 2017, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

    Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

    Report Highlights

    Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 16, 4, 16 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 2 and 4 molecules, respectively.

    Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
    -The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 6
    Global Markets Direct Report Coverage 6
    Osteosarcoma-Overview 7
    Osteosarcoma-Therapeutics Development 8
    Pipeline Overview 8
    Pipeline by Companies 9
    Pipeline by Universities/Institutes 12
    Products under Development by Companies 13
    Products under Development by Universities/Institutes 16
    Osteosarcoma-Therapeutics Assessment 17
    Assessment by Target 17
    Assessment by Mechanism of Action 20
    Assessment by Route of Administration 23
    Assessment by Molecule Type 25
    Osteosarcoma-Companies Involved in Therapeutics Development 27
    Advaxis Inc 27
    Advenchen Laboratories LLC 27
    Amgen Inc 28
    AntiCancer Inc 28
    Arrowhead Pharmaceuticals Inc 29
    AVEO Pharmaceuticals Inc 29
    Bayer AG 30
    Bellicum Pharmaceuticals Inc 30
    Boehringer Ingelheim GmbH 31
    Bristol-Myers Squibb Company 31
    Celldex Therapeutics Inc 32
    Cellmid Ltd 32
    CorMedix Inc 33
    Daiichi Sankyo Company Ltd 33
    Eisai Co Ltd 34
    Eleison Pharmaceuticals LLC 34
    Intezyne Technologies Inc 35
    Ipsen SA 35
    Isofol Medical AB 36
    Johnson & Johnson 36
    MacroGenics Inc 37
    MD Biosciences GmbH 37
    Merck & Co Inc 38
    Merck KGaA 38
    Novartis AG 39
    Oncolys BioPharma Inc 39
    Pfizer Inc 40
    Teijin Pharma Ltd 40
    Osteosarcoma-Drug Profiles 41
    12-B80-Drug Profile 41
    3D-QM-Drug Profile 42
    3D-QMS-Drug Profile 43
    A-1R-Drug Profile 44
    ADXS-HER2-Drug Profile 46
    aldoxorubicin hydrochloride-Drug Profile 50
    AM-7209-Drug Profile 68
    apatinib-Drug Profile 69
    AT-69-Drug Profile 75
    AU-101-Drug Profile 76
    AV-203-Drug Profile 77
    avelumab-Drug Profile 80
    axitinib-Drug Profile 91
    BMTP-11-Drug Profile 97
    CAB-102-Drug Profile 99
    Cellular Immunotherapy for GD2 Expressing Solid Tumors-Drug Profile 101
    Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma-Drug Profile 103
    Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 104
    Celyvir-Drug Profile 105
    cisplatin SR-Drug Profile 106
    daunorubicin hydrochloride-Drug Profile 108
    dihydroartemisinin-Drug Profile 109
    DS-5272-Drug Profile 110
    enoblituzumab-Drug Profile 111
    everolimus-Drug Profile 114
    glembatumumab vedotin-Drug Profile 126
    ipilimumab + nivolumab-Drug Profile 132
    irinotecan hydrochloride-Drug Profile 140
    JNJ-7107-Drug Profile 152
    lenvatinib mesylate-Drug Profile 155
    ligerin-Drug Profile 169
    MD-401A-Drug Profile 170
    Minnelide-Drug Profile 171
    Modufolin-Drug Profile 173
    Monoclonal Antibody for Osteosarcoma-Drug Profile 176
    Monoclonal Antibody to Inhibit GD2 for Oncology-Drug Profile 177
    Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma-Drug Profile 178
    OBP-702-Drug Profile 180
    Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer-Drug Profile 181
    pazopanib hydrochloride-Drug Profile 182
    pembrolizumab-Drug Profile 190
    radium Ra 223 dichloride-Drug Profile 251
    RSF-101-Drug Profile 260
    SEN-461-Drug Profile 262
    sirolimus albumin-bound-Drug Profile 263
    Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma-Drug Profile 265
    Small Molecules to Inhibit CaMKII for Osteosarcoma-Drug Profile 266
    Small Molecules to Inhibit MDM2 for Osteosarcoma-Drug Profile 267
    taurolidine-Drug Profile 268
    Vaccine for Osteosarcoma-Drug Profile 269
    VIMO-001-Drug Profile 270
    Osteosarcoma-Dormant Projects 271
    Osteosarcoma-Discontinued Products 273
    Osteosarcoma-Product Development Milestones 274
    Featured News & Press Releases 274
    Appendix 282
    Methodology 282
    Coverage 282
    Secondary Research 282
    Primary Research 282
    Expert Panel Validation 282
    Contact Us 282
    Disclaimer 283

    List of Tables
    Number of Products under Development for Osteosarcoma, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Products under Development by Companies, H2 2017 (Contd..2), H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Osteosarcoma-Pipeline by Advaxis Inc, H2 2017
    Osteosarcoma-Pipeline by Advenchen Laboratories LLC, H2 2017
    Osteosarcoma-Pipeline by Amgen Inc, H2 2017
    Osteosarcoma-Pipeline by AntiCancer Inc, H2 2017
    Osteosarcoma-Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017
    Osteosarcoma-Pipeline by AVEO Pharmaceuticals Inc, H2 2017
    Osteosarcoma-Pipeline by Bayer AG, H2 2017
    Osteosarcoma-Pipeline by Bellicum Pharmaceuticals Inc, H2 2017
    Osteosarcoma-Pipeline by Boehringer Ingelheim GmbH, H2 2017
    Osteosarcoma-Pipeline by Bristol-Myers Squibb Company, H2 2017
    Osteosarcoma-Pipeline by Celldex Therapeutics Inc, H2 2017
    Osteosarcoma-Pipeline by Cellmid Ltd, H2 2017
    Osteosarcoma-Pipeline by CorMedix Inc, H2 2017
    Osteosarcoma-Pipeline by Daiichi Sankyo Company Ltd, H2 2017
    Osteosarcoma-Pipeline by Eisai Co Ltd, H2 2017
    Osteosarcoma-Pipeline by Eleison Pharmaceuticals LLC, H2 2017
    Osteosarcoma-Pipeline by Intezyne Technologies Inc, H2 2017
    Osteosarcoma-Pipeline by Ipsen SA, H2 2017
    Osteosarcoma-Pipeline by Isofol Medical AB, H2 2017
    Osteosarcoma-Pipeline by Johnson & Johnson, H2 2017
    Osteosarcoma-Pipeline by MacroGenics Inc, H2 2017
    Osteosarcoma-Pipeline by MD Biosciences GmbH, H2 2017
    Osteosarcoma-Pipeline by Merck & Co Inc, H2 2017
    Osteosarcoma-Pipeline by Merck KGaA, H2 2017
    Osteosarcoma-Pipeline by Novartis AG, H2 2017
    Osteosarcoma-Pipeline by Oncolys BioPharma Inc, H2 2017
    Osteosarcoma-Pipeline by Pfizer Inc, H2 2017
    Osteosarcoma-Pipeline by Teijin Pharma Ltd, H2 2017
    Osteosarcoma-Dormant Projects, H2 2017
    Osteosarcoma-Dormant Projects, H2 2017 (Contd..1), H2 2017
    Osteosarcoma-Discontinued Products, H2 2017

    List of Figures
    Number of Products under Development for Osteosarcoma, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Advaxis Inc
    Advenchen Laboratories LLC
    Amgen Inc
    AntiCancer Inc
    Arrowhead Pharmaceuticals Inc
    AVEO Pharmaceuticals Inc
    Bayer AG
    Bellicum Pharmaceuticals Inc
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Celldex Therapeutics Inc
    Cellmid Ltd
    CorMedix Inc
    Daiichi Sankyo Company Ltd
    Eisai Co Ltd
    Eleison Pharmaceuticals LLC
    Intezyne Technologies Inc
    Ipsen SA
    Isofol Medical AB
    Johnson & Johnson
    MacroGenics Inc
    MD Biosciences GmbH
    Merck & Co Inc
    Merck KGaA
    Novartis AG
    Oncolys BioPharma Inc
    Pfizer Inc
    Teijin Pharma Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//osteosarcoma-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//osteosarcoma-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//osteosarcoma-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments